Granulocyte-Macrophage Colony-Stimulating Factor

Publication Title: 
Immunology Series

Table 1 summarizes the activities of hemopoietins on immature and mature basophils. IL-3, GM-CSF, and IL-5 enhanced basophil histamine release and in-vitro survival, while G-CSF, M-CSF, and IL-4 had no enhancing activities at all. In addition, IL-3 and GM-CSF induced basophil chemotaxis.

Hirai, K.
Morita, Y.
Miyamoto, T.
Publication Title: 
International Journal of Oncology

Granulocyte macrophage colony-stimulating factor (GM-CSF) is a key cytokine for the generation and stimulation of dendritic cells (DCs), and it may also play a pivotal role in promoting the survival of DCs. In this study, the feasibility of creating a cancer vaccine using DCs adenovirally transduced with the carcinoembryonic antigen (CEA) gene and the GM-CSF gene was examined. In addition, the effect of the co-transduction of GM-CSF gene on the lifespan of these genetically modified DCs was determined.

Ojima, Toshiyasu
Iwahashi, Makoto
Nakamura, Masaki
Matsuda, Kenji
Nakamori, Mikihito
Ueda, Kentaro
Naka, Teiji
Katsuda, Masahiro
Miyazawa, Motoki
Yamaue, Hiroki
Publication Title: 

CD34+ precursors in normal human bone marrow (BM) generate large numbers of dendritic cells alongside macrophages and granulocytic precursors when cultured for 12 to 14 days in c-kit ligand, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor-alpha (TNF-alpha). This study reports an intermediate cell type that develops by day 6, and has the potential to differentiate into either macrophages or dendritic cells.

Szabolcs, P.
Avigan, D.
Gezelter, S.
Ciocon, D. H.
Moore, M. A.
Steinman, R. M.
Young, J. W.
Publication Title: 
Cancer immunology, immunotherapy: CII

Bone marrow myelotoxicity is a major limitation of chemotherapy. While granulocyte colony stimulating factor (G-CSF) treatment is effective, alternative approaches to support hematopoietic recovery are sought. We previously found that a beta-glucan extract from maitake mushroom Grifola frondosa (MBG) enhanced colony forming unit-granulocyte monocyte (CFU-GM) activity of mouse bone marrow and human hematopoietic progenitor cells (HPC), stimulated G-CSF production and spared HPC from doxorubicin toxicity in vitro.

Lin, Hong
de Stanchina, Elisa
Zhou, Xi Kathy
Hong, Feng
Seidman, Andrew
Fornier, Monica
Xiao, Wei-Lie
Kennelly, Edward J.
Wesa, Kathleen
Cassileth, Barrie R.
Cunningham-Rundles, Susanna
Publication Title: 
PloS One

γδ T cells have been postulated to act as a first line of defense against infectious agents, particularly intracellular pathogens, representing an important link between the innate and adaptive immune responses. Human γδ T cells expand in the blood of brucellosis patients and are active against Brucella in vitro. However, the role of γδ T cells in vivo during experimental brucellosis has not been studied. Here we report TCRδ(-/-) mice are more susceptible to B. abortus infection than C57BL/6 mice at one week post-infection as measured by splenic colonization and splenomegaly.

Skyberg, Jerod A.
Thornburg, Theresa
Rollins, Maryclare
Huarte, Eduardo
Jutila, Mark A.
Pascual, David W.
Publication Title: 
Journal of Immunology (Baltimore, Md.: 1950)

Invariant NKT (iNKT) cells are a subset of T lymphocytes that recognize glycolipid Ags presented by the MHC class I-related protein CD1d. Activation of iNKT cells with glycolipid Ags, such as the marine sponge-derived reagent α-galactosylceramide (α-GalCer), results in the rapid production of a variety of cytokines and activation of many other immune cell types.

Parekh, Vrajesh V.
Wu, Lan
Olivares-Villagómez, Danyvid
Wilson, Keith T.
Van Kaer, Luc
Publication Title: 
Biological & Pharmaceutical Bulletin

OBJECTIVE: To investigate the clinical effects and security of YiSuiShengXueGranule (YSSXG) on treating 156 patients with beta-thalassemia major. METHODS: YSSXG was given orally to 156 patients with beta-thalassemia in GuangXi Autonomous Region (the high incidence area of beta-thalassemia in China) for 3 months as one therapeutic course, 3 times a day, 10 g each time (for children, the dose should be reduced properly according to their body weight and age), and no blood transfusion used during the course.

Fang, Suping
Wu, Zhikui
Zhang, Xinhua
Liu, Yongmei
Wang, Wenjuan
Chai, Limin
Cai, Huiguo
Yi, Jie
Wang, Lei
Chen, Yuying
Lv, Xinxia
Huang, Youwen
Wang, Rongxin
Chen, Peizhen
Publication Title: 
Journal of Neurosurgery. Spine

OBJECT: The aim in this study was to determine whether granulocyte-macrophage colony-stimulating factor (GM-CSF) leads to sensory improvement in rat spinal cord injury (SCI) models. METHODS: Thirty male Sprague-Dawley rats were included in this study: 10 in the sham group (laminectomy alone without SCI), 10 in the SCI group (SCI treated with phosphate-buffered saline), and 10 in the GM-CSF treatment group (SCI treated with GM-CSF). A locomotor function test and pain sensitivity test were conducted weekly for 9 weeks after SCI or sham injury.

Kim, Ji Yong
Oh, Chang Hyun
Huang, Xian
Kim, Moon Hang
Yoon, Seung Hwan
Kim, Kil Hwan
Park, Hyeonseon
Park, Hyung Chun
Park, So Ra
Choi, Byung Hyune
Subscribe to RSS - Granulocyte-Macrophage Colony-Stimulating Factor